about
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteriaToxicity after prolonged (more than four weeks) administration of intravenous colistinAerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosisWorldwide research productivity in critical care medicine.The significance of different formulations of aerosolized colistin.Infections of respiratory or abdominal origin in ICU patients: what are the differences?Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremiaPotential of old-generation antibiotics to address current need for new antibiotics.Colistin and polymyxin B in critical care.Pulmonary drug delivery systems for antimicrobial agents: facts and myths.Comparison of the distribution of citations received by articles published in high, moderate, and low impact factor journals in clinical medicine.Multidrug-resistant Gram-negative infections: the use of colistin.Pharmacokinetic evaluation of colistin sodium.Trimethoprim/sulfametrole: evaluation of the available clinical and pharmacokinetic/pharmacodynamic evidence.The revival of fosfomycin.A bibliometric analysis by geographic area of published research in several biomedical fields, 1995-2003.Gangrenous, hemorrhagic, bullous cellulitis associated with pseudomonas aeruginosa in a patient with Waldenström's macroglobulinemia.Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials.Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients.Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user.Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients.Open-access world wide web resources on sepsis.Plesiomonas shigelloides sepsis in a thalassemia intermedia patient.Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.Outcome of critically ill oldest-old patients (aged 90 and older) admitted to the intensive care unit.Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials.Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.Treatment of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii pneumonia.Aerosolized antibiotics: the past, present and future, with a special emphasis on inhaled colistin.Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.A bibliometric analysis of global research production in respiratory medicine.Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime.The incidence of adult respiratory distress syndrome in patients undergoing off-pump coronary artery bypass grafting surgery.High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury.Determinants of hospital mortality after coronary artery bypass grafting.The ingredients of a successful donation by brain death program in Greece.
P50
Q24794555-FEABDAF7-1312-4C1D-9DB9-32B6A8C90BCEQ24798835-3C1436C4-4488-4916-99B0-F9F4EBB9FB08Q24802737-82EB2117-E839-4AD8-B349-9E02E97C2470Q24811739-3F902E8A-4E66-4695-9845-9BB957852B92Q24817033-82A5B72D-F7CD-4124-AEEA-18868AF1673EQ33919050-4C398E64-433B-4DD9-9E20-7760CF713146Q34064473-A2E977BF-8C3B-4219-A344-4099C54058FDQ34721651-27E34405-B3CE-469C-B3DB-09AAC5E8FA25Q34850409-1E6327D4-0809-4EF1-9EEE-633D98427CB7Q37117236-89806023-1643-4F85-9216-C73F758B1438Q37638864-1977A51D-F951-4A87-9C75-50D18E165EF4Q37780800-B342C619-FF0A-497C-83A7-B8F3D3246FBBQ37785545-6E8E24F8-7F96-4CA3-B397-6591B27E0D7AQ37815508-B6783EEE-5B36-4110-8C93-D84E147C558EQ37899459-4EA87281-9E79-4A1C-A684-21B19C790B3FQ37938425-9C79FAFD-9BE3-4F5B-9EF3-864F8226B1B5Q39095889-F5F3CF58-CF1D-43DD-A2E6-2BD5AC17CA20Q40440986-5567C3F5-7DBE-456F-B5E3-0B3906ADF2AAQ42094286-F24FB57C-F93E-4F2F-91FE-AEB38AA654BEQ43223792-7235BE87-835E-411B-BBE1-F18350A3C013Q43289024-91A69E12-9833-4ECE-B5AC-C2BBDE5A2E12Q43565870-4F0B818A-C30A-4D60-A4C0-15C292F33964Q43592326-3E97759B-90D4-42B1-8FFD-35AFB5A28E2DQ43984630-B7C79B68-4C40-462C-90E5-4F4176264015Q44148289-F3F6ACF2-3E43-4647-92A9-9A89BB8A38F0Q44175552-6AB32D5A-AFAA-4165-A276-8975D2B80596Q44186929-82688D6E-BE11-4162-BD0E-954B08775C8BQ44830796-749D5576-A725-407C-8F29-904B71B0089DQ44850427-F897B616-8C06-4ED2-B79E-06065924C510Q44965585-295C6678-8402-4D17-BE87-3D3A397AD5CDQ45168346-419BB33C-D39D-4D78-9845-3DFA7D12EF71Q45246731-879AC876-53FC-4027-83C9-CC970A2940BCQ45260700-B11FA7C8-CEDB-4942-8E90-3BE283E7ED71Q46177552-17F987D6-BC9C-47AE-97C6-7373D104CDD2Q46512048-3C13B25D-1BD1-4DC6-8A52-0B6F3AD91D00Q46913918-BB8A6A7E-F1BF-4342-88A7-8D2180C0C2A4Q47660778-8A9098FD-2230-41EE-8DC0-53B8DDC68833Q47686610-264A508E-EF4C-4F92-B17F-C60749788F43Q48180290-FF30B3FD-57D6-4259-88CE-DFD0B1779CADQ48655321-7B14193F-9360-4A0D-BFEA-F29F548296CC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Argyris S Michalopoulos
@nl
Argyris S Michalopoulos
@sl
Argyris S. Michalopoulos
@en
Argyris S. Michalopoulos
@es
type
label
Argyris S Michalopoulos
@nl
Argyris S Michalopoulos
@sl
Argyris S. Michalopoulos
@en
Argyris S. Michalopoulos
@es
prefLabel
Argyris S Michalopoulos
@nl
Argyris S Michalopoulos
@sl
Argyris S. Michalopoulos
@en
Argyris S. Michalopoulos
@es
P106
P1153
7006049865
P21
P31
P496
0000-0002-6904-164X